^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JS007

    i
    Other names: JS007
    Associations

    News

    Trials
    Company:
    Shanghai Junshi Biosci
    Drug class:
    CTLA4 antagonist
    Related drugs:
    Associations

    News

    Trials
    7ms
    FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov)
    P1/2, N=117, Not yet recruiting, Fudan University
    New P1/2 trial
    |
    gemcitabine • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • leucovorin calcium • tifcemalimab (TAB004) • JS007
    over1year
    A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors (ESMO 2023)
    Conclusions JS007 is well-tolerated with preliminary promising efficacy in heavily pretreated pts. The dose expansion phase is still ongoing, and the combination of JS007 with the anti-PD-1 antibody toripalimab is planned.
    Clinical • P1 data • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Loqtorzi (toripalimab-tpzi) • JS007